Harwin Peter Evan 4

What Happened
Multiple related parties tied to Apogee Therapeutics reported sales on 2026-01-22. Fairmount Funds Management LLC (investment manager), Fairmount Healthcare Fund II L.P. (the fund), and two directors — Tomas Kiselak and Peter Harwin — each disposed of 1,750,000 shares at $76.30 per share. Each reported sale equals $133,525,000 in proceeds. These transactions are sales (not purchases) and therefore are not a direct bullish signal; they represent dispositions of non‑voting common stock that are convertible into voting common stock under specified limits.

Key Details

• Transaction date: 2026-01-22; price: $76.30 per share.
• Reported quantity per reporting party: 1,750,000 shares; proceeds per reporting party: $133,525,000.
• Shares owned after transaction: Not reported in the materials provided.
• Footnote highlights:
  • F1: Fairmount Funds Management LLC is the investment manager for Fairmount Healthcare Fund II L.P.; Peter Harwin and Tomas Kiselak are managers of Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership except for any pecuniary interest.
  • F2: The sold securities were non‑voting common stock convertible 1‑for‑1 into voting common stock, subject to conversion caps (generally a 9.99% ownership cap unless changed with notice, up to 19.99%).
• Filing timeliness: Reported and filed with a report date of 2026-01-22 (no late‑filing indication in the provided data).
• No indication in the filing of a 10b5-1 plan, cashless exercise, gift, or tax‑withholding disposition method.

Context: These entries reflect institutional/fund and director‑linked sales rather than an executive purchase. Because of the reporting relationships (manager, fund, and directors), some entries may reflect related parties rather than strictly independent sellers; avoid inferring company outlook solely from this routine reporting.